News & Articles

Collaboration integrates LucentAD Complete into AI‑driven clinical workflows to support earlier detection and treatment decisions

Certification reaffirms assay results are aligned with specialized mass spectrometry testing method

Anthropic’s agentic AI assistant connects with the Sapio Platform to enable data discovery, analysis, and action from a single prompt

Test enables identification of patients whose tumors express PD-L1 for potential treatment with KEYTRUDA (pembrolizumab)

Conference tackles regulatory alignment, digital twins and omics data

Presentations on Open Aperture, Apertura's material transfer agreement program, describe how open academic access to TfR1 CapX can unlock innovation and collaboration across the field

Expanded partnership aims to advance precision oncology through distributed NGS‑based tissue and liquid biopsy testing

A study led by Karl Landsteiner University shows that the disease affects whole-brain communication networks, and that this may help predict survival

In research conducted in mice, scientists identified a trio of existing medicines as promising candidates for treating a rare and severe form of infant leukemia caused by a genetic changed called KMT2A::AFF1

Prospective study published in Clinical Cancer Research shows that women >70 who tested Signatera MRD-negative could avoid surgery and remain progression-free

Drug Discovery USA 2026 to focus on emerging multifunctional small molecule and biologic approaches to drug difficult targets

Collaboration aims to discover and develop antibodies against multiple therapeutic targets designated by Merck

The U.S. FDA has cleared the Investigational New Drug (IND) application for ABSK061, a highly selective small-molecule FGFR2/3 inhibitor, for the treatment of children with achondroplasia (ACH)

Prospective UT MD Anderson study shows RNA analysis expands on treatment options beyond DNA testing

The treatment preserved quality of life

IDE approval by the FDA expands global trial to the United States as first study participant is treated in the United Kingdom

Co-occurrence of myocarditis with myositis and myasthenia gravis may also increase risk of death

Data presented at the AACR 2026 revealed a 44% reduction and growing urban concentration of U.S. phase I NSCLC trial sites between 2020 and 2024

This approach may eventually help guide personalized treatment decisions for patients diagnosed with these cancers

All patients were negative for minimal residual disease, and no patients experienced progression to active multiple myeloma during the median 15.3 months of follow-up

National Institutes of Health awards The Research OutSmarts Endometriosis team an $850,000 prize over one year to accelerate the development of a non-invasive diagnostic test

A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic NSCLC

The AACR will present the 2026 AACR Award for Lifetime Achievement in Cancer Research to Dr. James P. Allison, Fellow of the AACR Academy, during the AACR Annual Meeting 2026

The investigational drug led to objective response and disease control in patients with late-stage disease

The AACR will present the 2026 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the AACR Annual Meeting 2026